title: Multimodal therapy of small cell lung cancer in TNM stages I through IIIa.
abstract: Since 1977, Innsbruck University Hospital has been employing a multimodal therapy concept for small cell bronchial carcinomas in stages I to IIIa. This concept includes all three treatment forms effective in this tumor, namely, chemotherapy, surgery, and radiotherapy. The therapy scheme is stage-dependent and begins in stages T1-3 N0-1 with lung resection and in stage N2 with chemotherapy. To date, 45 patients have been included in a prospective, nonrandomized (phase II) trial: 7 in TNM stage I, 11 in stage II, and 27 in stage IIIa (6 T3 and 21 N2). The actuarial 5-year survival rate of the entire group (including therapy-related lethality, early recurrences, and protocol violations) is 36%; it is 57% for those in stage I, 28% for those in stage II, and 34% for those in stage IIIa. Median survival time is 18 months. Patients with completed multimodal treatment have a 5-year survival rate of 56% regardless of disease stage. Three patients died of tumor-unrelated causes after 47, 52, and 54 months.
authors.affiliation: Department of Surgery II, University of Innsbruck, Austria.
authors.forename: L C
authors.initials: LC
authors.lastname: Müller
authors.forename: G M
authors.initials: GM
authors.lastname: Salzer
authors.forename: H
authors.initials: H
authors.lastname: Huber
authors.forename: C
authors.initials: C
authors.lastname: Prior
authors.forename: I
authors.initials: I
authors.lastname: Ebner
authors.forename: H
authors.initials: H
authors.lastname: Frommhold
authors.forename: H W
authors.initials: HW
authors.lastname: Präuer
mesh_terms: D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011183:Postoperative Complications; D015996:Survival Rate